

Adult Post-Transplant Immunisation Protocol – Years 1-3

Time Post Transplant	Details	
4 months	1. Pneumococcal conjugate vaccine, PCV (13 serotypes)	1. One injection (Prevenar13®)
5 months	1. Pneumococcal conjugate vaccine, PCV (13 serotypes)	1. One injection (Prevenar13®)
6 months	1. Pneumococcal conjugate vaccine, PCV (13 serotypes)	1. One injection (Prevenar13®)
	2. Diphtheria, Tetanus, Pertussis (whooping cough), Polio, <i>Haemophilus influenzae</i> type b (Hib) and hepatitis B (DTaP/IPV/Hib/HepB)	2. One injection (Infanrix hexa® or Vaxelis®)
	3. Meningococcal group B (MenB)	3. One injection (Bexsero®)
	4. Shingles (herpes zoster) (<i>All adults over 18 yrs of age</i>)	4. One Injection Shingrix®
7 months	1. Diphtheria, Tetanus, Pertussis (whooping cough), Polio, <i>Haemophilus influenzae</i> type b (Hib) and hepatitis B (DTaP/IPV/Hib/HepB)	1. One injection (Infanrix hexa® or Vaxelis®)
8 months	1. Diphtheria, Tetanus, Pertussis (whooping cough), Polio, <i>Haemophilus influenzae</i> type b (Hib) and hepatitis B (DTaP/IPV/Hib/HepB)	1. One injection (Infanrix hexa® or Vaxelis®)
	2. Meningococcal group B (MenB) (<i>At least 8 weeks after 1st dose</i>)	2. One injection (Bexsero®)
	3. Shingles (herpes zoster) (<i>At least 8 weeks after 1st dose</i>)	3. One injection Shingrix®
	4. MenACWY	4. One injection (Nimenrix®, Menveo®, or MenQuadfi®)
18 months	1. Pneumococcal polysaccharide vaccine, PPV (23 serotypes) OR Pneumococcal conjugate vaccine, PCV (13 serotypes) (<i>PCV 13 serotype for patients with ongoing active graft v host disease</i>)	1. One injection (Non-proprietary) OR One injection (Prevenar13®) (<i>BMT team to advise which to administer</i>)
	2. MenACWY	2. One injection (Nimenrix®, Menveo®, or MenQuadfi®)
	3. Meningococcal group B (MenB)	3. One injection (Bexsero®)
	4. HPV (<i>To commence in all patients 12 - 25 yrs of age</i>)	5. Gardasil 9®
19 months	1. HPV (<i>1 month after 1st dose</i>)	1. Gardasil 9®
24 months	1. HPV (<i>At least 3 months after 2nd dose</i>)	1. Gardasil 9®
	2. MMR (<i>Patient MUST meet eligibility for live vaccine see over*</i>)	2. MMR VaxPro® or Priorix®
30 months	1. MMR (<i>6 months after 1st dose</i>) (<i>Patient MUST meet eligibility for live vaccine see over*</i>)	1. MMR VaxPro® or Priorix®
36 months	1. DTaP/IPV booster	1. Repevax® or Boostrix®

Notes: Please also see reverse for important notes

Keywords: Vaccinations, Immunisation, Post-Transplant	SOP or Protocol reference:	N/A
	Approved by: SWBMT Group	Date of approval: 01 September 2023
It is the responsibility of the user of this document to confirm that this is the current version by checking on the Cardiff and Vale UHB SharePoint site		

Adult Post-Transplant Immunisation Protocol – Years 1-3

To the BMT Team:

1. Consider deferring start of immunisations if patient receiving equivalent of prednisolone >0.5 mg/kg/day if rapid wean likely – all patients must have a clear plan to commence immunisations if deferral considered with communication to GP

To the GP:

1. The annual (seasonal) influenza vaccine is to be given every autumn providing it is at least 3 months post-transplant.
2. **COVID-19 vaccination** should follow the latest national policy as per the Green Book Chapter 14a. Information on co-administration with other vaccines is also detailed here.
3. *Live attenuated vaccines are **contraindicated** for patients within the first 2 years of transplant and patients must meet the following criteria before administration: (1) No active GvHD; (2) No systemic immunosuppression for 12 months (including monoclonal antibodies); (3) No intravenous immunoglobulin (IVIg) in last 3 months; (4) Not receiving maintenance chemotherapy. Please consult the transplant team BEFORE any live vaccines are considered.
4. *Live attenuated vaccines **MUST NOT** be administered to household contacts if the patient is within 2 months of BMT or if on active treatment for GvHD. This also applies to Rotavirus vaccination in household contacts and in addition the patient must avoid contact with the infants stool for 4 weeks after vaccination.
5. Td/IPV (Revaxis®) booster vaccination should be considered at 14 years post transplant.

References:

1. ECIL-7 consensus document (2017), Guidelines for vaccination of patients with haematological malignancies and HSCT recipients.
2. Joint consensus statement on the vaccinations of adult and paediatric haematopoietic stem cell transplant recipients. Miller et al Journal of Infection 2022
3. The Green Book [Greenbook title page and index \(publishing.service.gov.uk\)](https://www.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/101427/greenbook_title_page_and_index.pdf)

Keywords: Vaccinations, Immunisation, Post-Transplant	SOP or Protocol reference:	N/A
	Approved by: SWBMT Group	Date of approval: 01 September 2023
It is the responsibility of the user of this document to confirm that this is the current version by checking on the Cardiff and Vale UHB SharePoint site		